2024-03-28T18:14:44Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1412612021-11-22T12:54:08Zcom_10261_118com_10261_6col_10261_371
Genome expression profiling-based identification and administration efficacy of host-directed antimicrobial drugs against respiratory infection by nontypeable Haemophilus influenzae
Euba, Begoña
Moleres, Javier
Segura, Víctor
Viadas, Cristina
Morey, Pau
Moranta, David
Leiva, José
de-Torres, Juan Pablo
Bengoechea, José Antonio
Garmendia, Juncal
Ministerio de Economía y Competitividad (España)
Instituto de Salud Carlos III
Nafarroako Gobernua
Centro de Investigación Biomédica en Red Enfermedades Respiratorias (España)
Therapies that are safe, effective, and not vulnerable to developing resistance are highly desirable to counteract bacterial infections. Host-directed therapeutics is an antimicrobial approach alternative to conventional antibiotics based on perturbing host pathways subverted by pathogens during their life cycle by using host-directed drugs. In this study, we identified and evaluated the efficacy of a panel of host-directed drugs against respiratory infection by nontypeable Haemophilus influenzae (NTHi). NTHi is an opportunistic pathogen that is an important cause of exacerbation of chronic obstructive pulmonary disease (COPD). We screened for host genes differentially expressed upon infection by the clinical isolate NTHi375 by analyzing cell whole-genome expression profiling and identified a repertoire of host target candidates that were pharmacologically modulated. Based on the proposed relationship between NTHi intracellular location and persistence, we hypothesized that drugs perturbing host pathways used by NTHi to enter epithelial cells could have antimicrobial potential against NTHi infection. Interfering drugs were tested for their effects on bacterial and cellular viability, on NTHi-epithelial cell interplay, and on mouse pulmonary infection. Glucocorticoids and statins lacked in vitro and/or in vivo efficacy. Conversely, the sirtuin-1 activator resveratrol showed a bactericidal effect against NTHi, and the PDE4 inhibitor rolipram showed therapeutic efficacy by lowering NTHi375 counts intracellularly and in the lungs of infected mice. PDE4 inhibition is currently prescribed in COPD, and resveratrol is an attractive geroprotector for COPD treatment. Together, these results expand our knowledge of NTHi-triggered host subversion and frame the antimicrobial potential of rolipram and resveratrol against NTHi respiratory infection.
J.M. is funded by Ph.D. studentship BES-2013-062644 from the Ministerio Economía y Competitividad-MINECO, Spain. This study was funded by grants from ISCIII (PS09/00130), the Ministerio Economía y Competitividad (MINECO SAF2012-31166), and the Departamento de Salud Gobierno Navarra (359/2012) to J.G. CIBERES is an initiative from ISCIII, Spain.
Peer Reviewed
2016-12-09T13:26:47Z
2016-12-09T13:26:47Z
2015-12
2016-12-09T13:26:48Z
artículo
http://purl.org/coar/resource_type/c_6501
issn: 1098-6596
Antimicrobial Agents and Chemotherapy 59(12): 7581-7592 (2015)
http://hdl.handle.net/10261/141261
10.1128/AAC.01278-15
http://dx.doi.org/10.13039/501100003329
http://dx.doi.org/10.13039/501100004587
26416856
#PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2012-31166
http://doi.org/10.1128/AAC.01278-15
Sí
none
American Society for Microbiology